Redeye updates its estimates following Surgical Science’s Q1 2025 report, which beat our projections thanks to segment Educational Products. The report leaves investors to disentangle a conclusion from strong Q1 figures, lowered 2026e targets, tariff uncertainty, and the effects of Surgical Science’s recent M&A. We update our estimates and valuation.
LÄS MER
